86 results
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
30 Oct 18
Blueprint Medicines Reports Third Quarter 2018 Financial Results
7:30am
American Society for Hematology (ASH) Annual Meeting and Exposition in December 2018.
Avapritinib: Gastrointestinal Stromal Tumors (GIST)
Blueprint … , including PDGFRA-driven GIST, third-line or later GIST, and second-line GIST, at the 2018 Connective Tissue Oncology Society (CTOS) Annual Meeting
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
16 Jun 21
FDA Approves Blueprint Medicines’ AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis
5:14pm
approval of a new therapy, AYVAKIT, brings much needed hope to these patients,” said Valerie Slee, Board Chair of The Mast Cell Disease Society … Disease Society has made to improve the understanding of this disease, pioneer new approaches to measuring the impact of therapeutic interventions
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
17 Aug 22
Other Events
7:28am
Director of The Mast Cell Disease Society. “Patients with SM continue to be challenged by efforts to avoid various triggers of everyday life while also … Cell Disease Society. We are excited by these results and further energized to work together with these exceptional investigators to transform
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
9 May 19
Blueprint Medicines Reports First Quarter 2019 Financial Results
7:32am
, respectively.
Present the registration dataset for avapritinib in PDGFRA Exon 18 mutant GIST and fourth-line GIST at the 2019 American Society of Clinical … of the European Hematology Society.
Present updated data from the Phase 1 ARROW trial of BLU-667 in RET-altered cancers at the 2019 ASCO Annual Meeting
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
26 Feb 19
Blueprint Medicines Reports Fourth Quarter and Full Year 2018 Financial Results
7:31am
Society 2018 Annual Meeting in November 2018 and disclosed plans to conduct the registration-enabling Phase 3 COMPASS-2L precision medicine trial … of avapritinib in third-line GIST.
Avapritinib: Systemic mastocytosis (SM):
Presented updated data from the Phase 1 EXPLORER trial at the American Society
8-K
lq4s1025bryd
3 Dec 18
Regulation FD Disclosure
4:01pm
8-K
q296pi gjb
4 Jun 19
Regulation FD Disclosure
7:30am
8-K
94wpywcqi pgq
21 Sep 20
Other Events
8:00am
8-K
p5zcfyg zndof
1 Oct 18
Regulation FD Disclosure
12:00am
8-K
ksvuo
15 Nov 18
Regulation FD Disclosure
8:45am
8-K
ybqqm
9 Dec 19
Blueprint Medicines Announces Initial Data from Phase 2 PIONEER Trial of Avapritinib
7:31am
8-K
ly5kqa
29 May 20
Regulation FD Disclosure
8:20am
8-K
01vwjn tk
3 Jun 19
Regulation FD Disclosure
9:11am
8-K
EX-99.1
204pq4cc fd3rd
27 Mar 19
Blueprint Medicines Announces Accelerated Regulatory Submission Plans and Recent Clinical Progress
4:10pm
8-K
EX-99.1
pw22 7qotcq45pw643gl
1 Oct 18
Regulation FD Disclosure
12:00am
8-K
EX-99.1
60mdsqv10lx30v
26 Oct 23
Blueprint Medicines Reports Third Quarter 2023 Results
7:00am
8-K
EX-99.1
e09q7cdjptty
1 Aug 19
Blueprint Medicines Reports Second Quarter 2019 Financial Results
7:31am
8-K
EX-99.1
ed6pnab824bux
2 Aug 23
Blueprint Medicines Reports Second Quarter 2023 Results
7:00am
8-K
EX-99.1
4j7rt2ua
21 Sep 20
Other Events
8:00am
8-K
EX-99.1
a8g67quuacf4nhxjin
16 Oct 19
Entry into a Material Definitive Agreement
6:51am